🚀 VC round data is live in beta, check it out!
ExpreS2ion Biotech Valuation Multiples
Discover revenue and EBITDA valuation multiples for ExpreS2ion Biotech and similar public comparables like Aton, Vivesto, Instituto Rosenbusch, Pila Pharma and more.
ExpreS2ion Biotech Overview
About ExpreS2ion Biotech
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy; ES2B-I002, a Cytomegalovirus (CMV) vaccine; and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
Founded
2015
HQ
Employees
19
Website
Financials (FY)
EV
$730K
ExpreS2ion Biotech Financials
ExpreS2ion Biotech reported last fiscal year revenue of $400K and negative EBITDA of ($5M).
In the same fiscal year, ExpreS2ion Biotech generated $15K in gross profit, ($5M) in EBITDA losses, and had net loss of ($4M).
ExpreS2ion Biotech P&L
In the most recent fiscal year, ExpreS2ion Biotech reported revenue of $400K and EBITDA of ($5M).
ExpreS2ion Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $400K | XXX | XXX | XXX |
| Gross Profit | — | XXX | $15K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 4% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($5M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1156%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (1211%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | — | XXX | (1041%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
ExpreS2ion Biotech Stock Performance
ExpreS2ion Biotech has current market cap of $6M, and enterprise value of $730K.
Market Cap Evolution
ExpreS2ion Biotech's stock price is $1.66.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $730K | $6M | 1.4% | XXX | XXX | XXX | $-1.18 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialExpreS2ion Biotech Valuation Multiples
ExpreS2ion Biotech trades at 1.8x EV/Revenue multiple, and (0.2x) EV/EBITDA.
ExpreS2ion Biotech Financial Valuation Multiples
As of March 11, 2026, ExpreS2ion Biotech has market cap of $6M and EV of $730K.
Equity research analysts estimate ExpreS2ion Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ExpreS2ion Biotech has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6M | XXX | $6M | XXX | XXX | XXX |
| EV (current) | $730K | XXX | $730K | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 1.8x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (0.2x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 48.7x | XXX | XXX | XXX |
| P/E | — | XXX | (1.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified ExpreS2ion Biotech Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
ExpreS2ion Biotech Margins & Growth Rates
ExpreS2ion Biotech's revenue in the last fiscal year grew by 21%.
ExpreS2ion Biotech Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 21% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (1156%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 0% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 273% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1214% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
ExpreS2ion Biotech Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Aton | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivesto | XXX | XXX | XXX | XXX | XXX | XXX |
| Instituto Rosenbusch | XXX | XXX | XXX | XXX | XXX | XXX |
| Pila Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Genxone | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ExpreS2ion Biotech M&A Activity
ExpreS2ion Biotech acquired XXX companies to date.
Last acquisition by ExpreS2ion Biotech was on XXXXXXXX, XXXXX. ExpreS2ion Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by ExpreS2ion Biotech
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialExpreS2ion Biotech Investment Activity
ExpreS2ion Biotech invested in XXX companies to date.
ExpreS2ion Biotech made its latest investment on XXXXXXXX, XXXXX. ExpreS2ion Biotech invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by ExpreS2ion Biotech
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout ExpreS2ion Biotech
| When was ExpreS2ion Biotech founded? | ExpreS2ion Biotech was founded in 2015. |
| Where is ExpreS2ion Biotech headquartered? | ExpreS2ion Biotech is headquartered in Sweden. |
| How many employees does ExpreS2ion Biotech have? | As of today, ExpreS2ion Biotech has over 19 employees. |
| Is ExpreS2ion Biotech publicly listed? | Yes, ExpreS2ion Biotech is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of ExpreS2ion Biotech? | ExpreS2ion Biotech trades under EXPRS2 ticker. |
| When did ExpreS2ion Biotech go public? | ExpreS2ion Biotech went public in 2016. |
| Who are competitors of ExpreS2ion Biotech? | ExpreS2ion Biotech main competitors are Aton, Vivesto, Instituto Rosenbusch, Pila Pharma. |
| What is the current market cap of ExpreS2ion Biotech? | ExpreS2ion Biotech's current market cap is $6M. |
| What is the current revenue of ExpreS2ion Biotech? | ExpreS2ion Biotech's last fiscal year revenue is $400K. |
| What is the current EV/Revenue multiple of ExpreS2ion Biotech? | Current revenue multiple of ExpreS2ion Biotech is 1.8x. |
| Is ExpreS2ion Biotech profitable? | No, ExpreS2ion Biotech is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.